MEDIGENE IMMUNOTHERAPIES
LIVE

Serial Number

79309216

Owner

Medigene Immunotherapies GmbH

Attorney

Lisa C. Pavento

Filing Date

Feb 23, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MEDIGENE IMMUNOTHERAPIES Trademark

Serial Number: 79309216 • Registration: 6932587

MEDIGENE IMMUNOTHERAPIES is a trademark filed by Medigene Immunotherapies GmbH on February 23, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Medigene Immunotherapies GmbH (3 trademarks)

Lochhamerstrasse 11
Planegg/Martinsried , DE

Entity Type: 03

Trademark Details

Filing Date

February 23, 2021

Registration Date

December 27, 2022

Published for Opposition

October 11, 2022

Goods & Services

Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods

Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy

Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 1, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 6, 2023 FICS
FINAL DISPOSITION PROCESSED
Apr 6, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 27, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 27, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 27, 2022 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 17, 2022 OPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 11, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 11, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Oct 10, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 28, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 28, 2022 OPNR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 21, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 21, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 21, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 7, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 7, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 7, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 7, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 7, 2022 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 14, 2022 GNFN
FINAL REFUSAL E-MAILED
Apr 14, 2022 GNFR
FINAL REFUSAL WRITTEN
Apr 14, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 30, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 30, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 30, 2022 TROA
REFUSAL PROCESSED BY IB
Oct 30, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 1, 2021 RFCS
REFUSAL PROCESSED BY MPU
Oct 1, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 27, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 26, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 17, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 27, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 23, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 22, 2021 REPR